Posters –
Infectious diseases & Vaccines
NAME OF THE PROJECT
NAME OF THE MAIN CONTACT
ORGANISATION NAME
Technology
Customers / Target market
Industry and competitors
Financing need / Commercial
opportunity
IP – Patent situation
Future steps / Milestones
AN ANTI-ALLERGIC DRUG TARGETING PI3K DELTA
Daphné Thomas - daphne.thomas@pulsalys.fr - +33 (0)4.26.23.56.78
PULSALYS
PI3Kinase delta is an enzyme expressed by few cell types including human basophils, a
type of white blood cell involved in allergy.
We have developed an inhibitor of PI3Kinase delta which potently inhibits degranulation
of stimulated normal human basophils and protects mice developing albumin-induced
allergic asthma.
This treatment was well tolerated when administred over a period of several weeks and
was associated with a sig-nificant reduction in the pulmonary cellular inflammatory
infiltrate.
ADVANTAGES / NOVELTY : Targeted therapy / Excellent / tolerance / Bioavailable by oral
or intravenous route / Simple and low-cost synthesis
Applications :
- Severe asthma, in particular in patients relying on large daily doses of steroids
and/or refractory to therapy.
- Secondary indications include other manifestation of allergy, including
cutaneous and mucosal manifestations.
Target market : Pharma industry
Pharma companies
We are looking for a partnership with pharma companies or subcontractors to
collaborate on the preclinical / clinical development of our therapeutic lead compound
for further licensing.
Patent pending in PCT
Priority date: April 5th, 2013 (FR1353091)
STAGE OF DEVELOPMENT :
The PI3Kinase inhibitor which we have developed has shown significant preclinical
activity with normal human stimulated basophils and in a preclinical mouse models of
allergic asthma. Non regulatory chronic exposure for periods up to 4 weeks showed no
sign of toxicity.
FUTURE STEPS:
Preclinical studies
Regulatory preclinical toxicity
First in man study in patients with severe asthma.
Further reading
N/A
Contact person
Daphné Thomas, Tech Transfer Officer – Health & Life Sciences, SATT Pulsalys,
daphne.thomas@pulsalys.fr - +33 (0)4.26.23.56.78